Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes

Le Pogam, Carole, Krief, Patricia, Beurlet, Stephanie, Soulié, Annie, Balitrand, Nicole, Cassinat, Bruno, Cavé, Helene, Kosmider, Olivier, Setterblad, Niclas, Leboeuf, Christophe, Sarda-Mantel, Laure, Hervatin, Florence, Merlet, Pascal, Noguera, Maria-Elena, Janin, Anne, Pla, Marika, Fontenay, Michaela, Adès, Lionel, Fenaux, Pierre, Chomienne, Christine, Padua, Rose Ann and Omidvar, Nader 2013. Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. Leukemia Research 37 (3) , pp. 312-319. 10.1016/j.leukres.2012.10.018

Full text not available from this repository.

Abstract

We have previously demonstrated that two prognostic features of myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML), mutant NRAS and over-expressing BCL-2, cooperate physically and functionally in vivo. Screening of MDS patient bone marrow (BM) identified NRAS:BCL-2 co-localization in 64% cases, correlating with percentage BM blasts, apoptotic features and disease status (p < 0.0001). Localization of the complex at the plasma membrane or the mitochondria correlated with disease and apoptosis features in MDS patients, whilst caspase-9 mediated mechanism was elucidated in vivo and in vitro. The intensity and localization of the RAS:BCL-2 complex merits further evaluation as a novel biomarker of MDS.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	RAS; BCL-2; AML; MDS; Apoptosis
Publisher:	Elsevier
ISSN:	0145-2126
Last Modified:	04 Jun 2017 08:17
URI:	https://orca.cardiff.ac.uk/id/eprint/75467

Citation Data

Cited 4 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item